ClinicalTrials.gg
Not yet recruitingNCT06791629PRAISEUpdated Jan 24, 2025

Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation

An interventional study of Pulsed Field Ablation and Radiofrequency Ablation in Persistent Atrial Fibrillation, Radiofrequency Catheter Ablation and Pulsed Field Ablation, sponsored by Beijing Anzhen Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
6th of 24
700 · median 410
Started
2025
with 10 others
No phase
21 of 36
15 open now
Primary completion
2026-12
later than 5 of 25 live
Registered
14th of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2025, is one of 21 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 14th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

This clinical trial aims to compare the efficacy and safety of pulsed field ablation and radiofrequency ablation to treat persistent atrial fibrillation in adults.

Participants will:

Undergo pulsed field ablation or radiofrequency ablation. Keep follow-up for at least 12 months.

Read the detailed description

Traditional treatment options for persistent atrial fibrillation (PeAF) include pharmacological management, electrical cardioversion, and catheter ablation. Pulmonary vein isolation (PVI) has become the cornerstone of ablation therapy and has been shown to be effective in clinical practice. However, its efficacy is relatively limited in patients with persistent AF compared with those with paroxysmal AF, and many patients still experience recurrence after treatment.

In recent years, linear ablation strategies based on alcohol ablation have been shown to improve the one-year maintenance of sinus rhythm in patients with PeAF. Traditional radiofrequency ablation (RF) has demonstrated good outcomes but still has certain limitations when dealing with PeAF. In several clinical studies, pulsed field ablation (PFA), an emerging and innovative technique, has shown non-inferiority in treating paroxysmal AF. Furthermore, PFA has also demonstrated significant efficacy in linear ablation sites such as the mitral isthmus line, posterior left atrial wall, and tricuspid isthmus line, highlighting its potential in treating PeAF. This study aims to compare the safety and efficacy of PFA and radiofrequency ablation (RF) in the treatment of PeAF through a multi-center, prospective, randomized, open-label, non-inferiority clinical trial, to provide a safer and more effective treatment option for clinical practice.

03

Conditions studied

  • Persistent Atrial Fibrillation
  • Radiofrequency Catheter Ablation
  • Pulsed Field Ablation

Browse trials for

Keywords

  • persistent atrial fibrillation
  • Radiofrequency Catheter Ablation
  • pulsed field ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-80 years
  • Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years)
  • Left atrial diameter on parasternal long-axis view of echocardiogram \< 50 mm
  • Agree to be randomly assigned to the ablation strategy and able to follow up

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation due to reversible causes
  • \< 30%
  • Severe congenital heart disease
  • Severe liver or kidney dysfunction ( \< 15, grade 3), or history of dialysis
  • History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement
  • History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure
  • to oral anticoagulation
  • Contraindications to right or left heart catheterization
  • Pregnancy
  • \< 1 year (e.g., advanced , end-stage renal disease)
  • Currently enrolled in another trial evaluating medical devices or drugs
  • Other situations where the investigator determines the subject is unsuitable for the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Active comparator
    Radiofrequency Ablation

    Device: Radiofrequency Ablation

  • Experimental
    Pulsed Field Ablation

    Device: Pulsed Field Ablation

Interventions

  • DevicePulsed Field Ablation

    Patients will be treated with pulsed field ablation for atrial fibrillation.

  • DeviceRadiofrequency Ablation

    Patients will be treated with radiofrequency ablation for atrial fibrillation.

06

What researchers measure

Primary outcomes

  1. Freedom from any documented atrial arrhythmia lasting for >30s in the absence of antiarrhythmic therapy in 12 months after the index ablation procedure (excluding a blanking period of 3 months)

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

Secondary outcomes

  1. Freedom from any documented atrial arrhythmia in 12 months after the index ablation procedure

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  2. Freedom from any documented atrial fibrillation lasting for >30s in 12 months after the index ablation procedure (excluding a blanking period of 3 months)

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  3. Freedom from any documented atrial tachycardia and atrial flutter episodes in 12 months after the index ablation procedure

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  4. Freedom from any documented atrial arrhythmia in the absence of antiarrhythmic therapy in 12 months after multiple ablation procedure (excluding a blanking period of 3 months)

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  5. The atrial fibrillation burden (percentage of time) monitored over 12 months

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  6. Cardiovascular-related hospitalizations in 12 months after the index ablation procedure

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  7. Perioperative complications in 30 days after the index ablation procedure

    Cardiac tamponade or perforation, permanent phrenic nerve palsy, acute coronary artery occlusion, stroke/thromboembolism/transient ischemic attack, pulmonary vein stenosis, left atrial-esophageal fistula, vascular complications requiring intervention (e.g., pseudoaneurysm, arteriovenous fistula), coronary artery spasm, renal failure due to hemolysis, death, and other treatment-related complications requiring intervention or prolonging hospitalization.

    Time frame: From the end of the ablation to the 30 days follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 22 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2025
First posted
Jan 24, 2025
StartEst.
Feb 15, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Feb 15, 2027
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06791629
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Feb 15, 2025 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Jan 24, 2025

Study contacts

Deyong Long
Contact
dragon2008@vip.sina.com
+86 135 2295 8166

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion